Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers.

Teng R, Maya J, Butler K.

Platelets. 2013;24(8):615-24. doi: 10.3109/09537104.2012.748185. Epub 2012 Dec 18.

2.

Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.

Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G.

Eur Heart J. 2006 May;27(9):1038-47. Epub 2006 Feb 13.

PMID:
16476694
3.

Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.

Butler K, Teng R.

Br J Clin Pharmacol. 2010 Jul;70(1):65-77. doi: 10.1111/j.1365-2125.2010.03669.x.

4.

Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.

Hiasa Y, Teng R, Emanuelsson H.

Cardiovasc Interv Ther. 2014 Oct;29(4):324-33. doi: 10.1007/s12928-014-0277-1. Epub 2014 Jun 17.

PMID:
24935072
5.

Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.

Traby L, Kollars M, Kaider A, Eichinger S, Wolzt M, Kyrle PA.

J Thromb Haemost. 2016 Feb;14(2):273-81. doi: 10.1111/jth.13216. Epub 2016 Jan 30.

6.

Pharmacokinetics and pharmacodynamics of ticagrelor and prasugrel in healthy male Korean volunteers.

Jeon HS, Kim MJ, Choi HY, Kim YH, Kim EH, Kim AR, Park HJ, Bae KS, Lim HS.

Clin Ther. 2015 Mar 1;37(3):563-73. doi: 10.1016/j.clinthera.2015.01.010. Epub 2015 Feb 16. Erratum in: Clin Ther. 2015 Sep 1;37(9):2149.

PMID:
25697420
7.

Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.

Li H, Butler K, Yang L, Yang Z, Teng R.

Clin Drug Investig. 2012 Feb 1;32(2):87-97. doi: 10.2165/11595930-000000000-00000.

PMID:
22168538
8.
9.

Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.

Guo LZ, Kim MH, Jin CD, Lee JY, Yi SJ, Park MK, Cho YR, Park TH.

Platelets. 2015;26(6):563-9. doi: 10.3109/09537104.2014.959913. Epub 2014 Oct 2.

PMID:
25275429
10.

Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.

Husted SE, Storey RF, Bliden K, Tantry US, Høimark L, Butler K, Wei C, Teng R, Gurbel PA.

Clin Pharmacokinet. 2012 Jun 1;51(6):397-409. doi: 10.2165/11599830-000000000-00000.

PMID:
22515556
11.

Pharmacokinetics and pharmacodynamics of the antiplatelet combination aspirin (acetylsalicylic acid) plus extended-release dipyridamole are not altered by coadministration with the potent CYP2C19 inhibitor omeprazole.

Offman E, Schobelock MJ, Brickl R, VanderMaelen CP, Ehrlich J, Eisert W.

Am J Cardiovasc Drugs. 2013 Apr;13(2):113-20. doi: 10.1007/s40256-013-0018-3.

PMID:
23532686
12.

Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers.

Teng R, Butler K.

Int J Clin Pharmacol Ther. 2014 Jun;52(6):478-91. doi: 10.5414/CP202017.

PMID:
24755129
13.

Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.

Li H, Guo J, Carlson GF, Teng R.

Br J Clin Pharmacol. 2016 Aug;82(2):352-61. doi: 10.1111/bcp.12950. Epub 2016 Jun 9.

14.

The effect of desmopressin on bleeding time and platelet aggregation in healthy volunteers administered ticagrelor.

Teng R, Mitchell PD, Butler K.

J Clin Pharm Ther. 2014 Apr;39(2):186-91. doi: 10.1111/jcpt.12130. Epub 2014 Jan 21.

PMID:
24444280
15.

Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.

Butler K, Teng R.

J Clin Pharmacol. 2011 Jul;51(7):978-87. doi: 10.1177/0091270010379409. Epub 2010 Oct 6.

PMID:
20926753
16.

Low-dose ticagrelor yields an antiplatelet efficacy similar to that of standard-dose ticagrelor in healthy subjects: an open-label randomized controlled trial.

Li P, Gu Y, Yang Y, Chen L, Liu J, Gao L, Qin Y, Cai Q, Zhao X, Wang Z, Ma L.

Sci Rep. 2016 Aug 24;6:31838. doi: 10.1038/srep31838.

17.
18.

Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.

Waksman R, Maya J, Angiolillo DJ, Carlson GF, Teng R, Caplan RJ, Ferdinand KC.

Circ Cardiovasc Interv. 2015 Jul;8(7):e002232. doi: 10.1161/CIRCINTERVENTIONS.114.002232.

19.

Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects.

Teng R, Mitchell P, Butler K.

Eur J Clin Pharmacol. 2013 Apr;69(4):877-83. doi: 10.1007/s00228-012-1436-x. Epub 2012 Oct 24.

PMID:
23093043
20.

Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L.

Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003.

PMID:
19332184

Supplemental Content

Support Center